Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Percy Ivy

Showing results (81-90 of 232) with videos related to

Pageof 24
Sort By:
Translational Oncology|August 9, 2022
Survey of Lifestyle, Past Medical History and Complementary and Alternative Medicine Use Among Adult Patients Participating in the National Cancer Institute's Exceptional Responders InitiativeOluwadamilola Olaku, Barbara A Conley, S Percy Ivy, et al.
JCO Clinical Cancer Informatics|January 18, 2019
Technology Applications: Use of Digital Health Technology to Enable Drug DevelopmentJoyce F Liu, Jung-Min Lee, Ellie Strock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trialsDavid M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
Cancer Chemotherapy and Pharmacology|August 8, 2012
Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumorsJoanna M Brell, Smitha S Krishnamurthi, Linda Rath, et al.
Investigational New Drugs|July 22, 2005
Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancerAfshin Dowlati, Robert Chapman, Shanmuga Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2013
Developing standards for breakthrough therapy designation in oncologySandra J Horning, Daniel A Haber, Wendy K D Selig, et al.
Oncotarget|February 17, 2015
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trialsDavid M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
The Oncologist|March 20, 2021
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA MutationJoseph W Kim, Dana B Cardin, Ulka N Vaishampayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignanciesShivaani Kummar, Larry Anderson, Kimberly Hill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2011
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malateGlenn Liu, Robert Jeraj, Matt Vanderhoek, et al.
Pageof 24

Showing results (81-90 of 232) with videos related to

Sort By:
Pageof 24
Translational Oncology|August 9, 2022
Survey of Lifestyle, Past Medical History and Complementary and Alternative Medicine Use Among Adult Patients Participating in the National Cancer Institute's Exceptional Responders InitiativeOluwadamilola Olaku, Barbara A Conley, S Percy Ivy, et al.
JCO Clinical Cancer Informatics|January 18, 2019
Technology Applications: Use of Digital Health Technology to Enable Drug DevelopmentJoyce F Liu, Jung-Min Lee, Ellie Strock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trialsDavid M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
Cancer Chemotherapy and Pharmacology|August 8, 2012
Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumorsJoanna M Brell, Smitha S Krishnamurthi, Linda Rath, et al.
Investigational New Drugs|July 22, 2005
Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancerAfshin Dowlati, Robert Chapman, Shanmuga Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2013
Developing standards for breakthrough therapy designation in oncologySandra J Horning, Daniel A Haber, Wendy K D Selig, et al.
Oncotarget|February 17, 2015
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trialsDavid M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
The Oncologist|March 20, 2021
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA MutationJoseph W Kim, Dana B Cardin, Ulka N Vaishampayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignanciesShivaani Kummar, Larry Anderson, Kimberly Hill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2011
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malateGlenn Liu, Robert Jeraj, Matt Vanderhoek, et al.
Pageof 24